Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 5/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5401671 | 0.93 | HPGD (0.52) | HTTHPGDALDH1A1KDM4ELMNA | |
| SCHEMBL5392409 | 0.90 | ALDH1A1 (0.50) | HTTHPGDALDH1A1KDM4ELMNA | |
| SCHEMBL5392452 | 0.90 | HTT (0.50) | MAPK1HTTHPGDALDH1A1KDM4E | |
| SCHEMBL5394637 | 0.89 | HPGD (0.54) | HTTHPGDALDH1A1KDM4ELMNA | |
| SCHEMBL5399560 | 0.89 | ALDH1A1 (0.47) | MAPK1HTTHPGDNAMPTALDH1A1 | |
| SCHEMBL5418440 | 0.89 | L3MBTL1 (0.52) | ALDH1A1KDM4EKMT2A | |
| SCHEMBL5401031 | 0.88 | HPGD (0.51) | HTTHPGDALDH1A1KDM4ELMNA | |
| SCHEMBL5397914 | 0.88 | MAPK1 (0.49) | MAPK1HTTALDH1A1POLBSMN1; SMN2 | |
| SCHEMBL5403468 | 0.88 | POLB (0.52) | HTTHPGDALDH1A1KDM4EPOLB | |
| SCHEMBL5409176 | 0.88 | MAPK1 (0.50) | MAPK1HTTHPGDNAMPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7285680-B2 | β-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-11-17 | — | — | US | disclosed |
| EP-1533294-A1 | BETA-ALANINE DERIVATIVE AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2005-05-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256160-A1 | Beta-alanine derivatives and the use thereof | TGFB1, PML, APOB | MAPK1 1369/4885HTT 3791/4885HPGD 1078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.